Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy

BACKGROUND: Homozygosity at HLA-I locus has been reported to be an unfavorable predictive biomarker of second-line or beyond immunotherapy in patients with different types of cancer. The linkage between HLA-I zygosity and survival in NSCLC patients treated with first-line immunotherapy with or witho...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dongyup, Park, Jonghanne, Choi, Horyun, Gim, Gahyun, Cho, Sukjoo, Kim, Leeseul, Oh, Youjin, Kang, Cyra Y., Kim, Yeseul, Tan, Dean, de Viveiros, Pedro Antonio Hermida, Chae, Young Kwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449023/
https://www.ncbi.nlm.nih.gov/pubmed/34568594
http://dx.doi.org/10.1016/j.heliyon.2021.e07916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449023/
https://www.ncbi.nlm.nih.gov/pubmed/34568594
http://dx.doi.org/10.1016/j.heliyon.2021.e07916

Ejemplares similares